127 related articles for article (PubMed ID: 15233210)
21. Somatostatin agonists for treatment of acromegaly.
Ben-Shlomo A; Melmed S
Mol Cell Endocrinol; 2008 May; 286(1-2):192-8. PubMed ID: 18191325
[TBL] [Abstract][Full Text] [Related]
22. Surgical-pharmacological interactions in the treatment of acromegaly.
Abreu C; Guinto G; Mercado M
Expert Rev Endocrinol Metab; 2019 Jan; 14(1):35-42. PubMed ID: 30595057
[TBL] [Abstract][Full Text] [Related]
23. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.
Matta MP; Couture E; Cazals L; Vezzosi D; Bennet A; Caron P
Eur J Endocrinol; 2008 Mar; 158(3):305-10. PubMed ID: 18299462
[TBL] [Abstract][Full Text] [Related]
24. Lanreotide autogel-induced tumour shrinkage in thyrotropin-secreting pituitary macroadenomas.
Paniagua AE; Bernabeu I; Leskela S; Marazuela M
Clin Endocrinol (Oxf); 2011 Mar; 74(3):406-8. PubMed ID: 21091752
[No Abstract] [Full Text] [Related]
25. [Excellent response to lanreotide treatment of thyrotropin and prolactin secreting pituitary macroadenoma].
Murillo Sanchís J; Martín AL; Salinas Vert I; Sanmartí Sala A
Med Clin (Barc); 2000 Feb; 114(6):238. PubMed ID: 10757110
[No Abstract] [Full Text] [Related]
26. Structure and function of somatostatin receptors in growth hormone control.
Shimon I; Melmed S
J Endocrinol; 1997 Oct; 155 Suppl 1():S3-6; discussion S7-8. PubMed ID: 9389989
[TBL] [Abstract][Full Text] [Related]
27. [Somatostatin analogs in the clinical management of pituitary neoplasms].
Colao A; Dorato M; Pulcrano M; Rossi FW; Auriemma RS; Lombardi G; Lastoria S
Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
[TBL] [Abstract][Full Text] [Related]
28. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
29. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
[TBL] [Abstract][Full Text] [Related]
30. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly.
Hua SC; Yan YH; Chang TC
Eur J Endocrinol; 2006 Dec; 155(6):831-7. PubMed ID: 17132752
[TBL] [Abstract][Full Text] [Related]
31. [Lanreotide++: a new therapeutic option in acromegaly].
Díez JJ
Med Clin (Barc); 1996 Sep; 107(7):257-69. PubMed ID: 8975096
[No Abstract] [Full Text] [Related]
32. Depot somatostatin analogs--a new first line therapy for acromegaly.
Robbins RJ
J Clin Endocrinol Metab; 1997 Jan; 82(1):15-7. PubMed ID: 8989224
[No Abstract] [Full Text] [Related]
33. Conclusions: the future role of somatostatin analogs.
Lamberts SW
J Endocrinol Invest; 2003; 26(8 Suppl):134-5. PubMed ID: 15233230
[No Abstract] [Full Text] [Related]
34. Comment of long-acting lanreotide inducing clinical and biochemical remission of acromegaly caused by disseminated GHRH secreting carcinoid.
Krassowski J; Zgliczyński W; Jeske W; Zgliczyński S
J Clin Endocrinol Metab; 1999 May; 84(5):1761-2. PubMed ID: 10323416
[No Abstract] [Full Text] [Related]
35. Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review.
Ertorer ME; Bakiner O; Anaforoglu I; Bozkirli E; Tutuncu NB; Demirag NG
Neuro Endocrinol Lett; 2007 Dec; 28(6):727-33. PubMed ID: 18063933
[TBL] [Abstract][Full Text] [Related]
36. [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
Losa M; Mortini P; Giovanelli M
Minerva Endocrinol; 2003 Mar; 28(1):39-51. PubMed ID: 12621362
[TBL] [Abstract][Full Text] [Related]
37. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
Caron P; Morange-Ramos I; Cogne M; Jaquet P
J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
[TBL] [Abstract][Full Text] [Related]
38. The quality of life and psychological, social and cognitive functioning of patients with acromegaly.
Szcześniak D; Jawiarczyk-Przybyłowska A; Rymaszewska J
Adv Clin Exp Med; 2015; 24(1):167-72. PubMed ID: 25923102
[TBL] [Abstract][Full Text] [Related]
39. Pituitary gangliocytoma-adenoma presenting with acromegaly: response to treatment.
Luna V; Morales F; Luengo LM; Sanz A; Diaz J
Arch Intern Med; 2001 Apr; 161(7):1010-1. PubMed ID: 11295968
[No Abstract] [Full Text] [Related]
40. [Medical treatment of pituitary adenoma].
Chanson P
Rev Prat; 1996 Jun; 46(12):1509-13. PubMed ID: 8881166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
